Exosomal miRNA in early-stage hepatocellular carcinoma  

作　　者：Zhi-Qiang Wu Yi-Xin Zhu Yun Jin Yin-Chu Zhan 

机构地区：[1]Department of Surgery,The Second People's Hosptal of Quzhou,Quzhou 324000,Zhejiang Province,China [2]Department of Surgery,The Second Affiliated Hospital,Zhejiang University,School of Medicine,Hangzhou 310009,Zhejiang Province,China

出　　处：《World Journal of Clinical Cases》2023年第3期528-533,共6页世界临床病例杂志

基　　金：Supported by the Quzhou Science and Technology Guided Project Planning,No.2019133。

摘　　要：The incidence and mortality of hepatic carcinoma(HCC)remain high,and early diagnosis of HCC is seen as a key approach in improving clinical outcomes.However,the sensitivity and specificity of current early screening methods for HCC are not satisfactory.In recent years,research around exosomal miRNA has gradually increased,and these molecules have emerged as attractive candidates for early diagnosis and treatment of HCC.This review summarizes the feasibility of using miRNAs in peripheral blood exosomes as early diagnostic tools for HCC.

关 键 词：Hepatic carcinoma Early diagnosis Exosomal miRNA BIOMARKER 

分 类 号：R735.7[医药卫生—肿瘤]